Back to search results

Study of TNG462 in Pancreatic and Lung Cancers with Specific Mutations

This study is testing TNG462 in combination with other drugs (RMC-6236, RMC-9805, mFOLFIRINOX, or gemcitabine/nab-paclitaxel) for people with pancreatic cancer (PDAC) or non-small cell lung cancer (NSCLC). You might be able to join if your cancer has a specific genetic change called an MTAP deletion, and for some parts of the study, also a RAS mutation. The study aims to find the safest dose and see how well these combinations work against cancer. The study is currently unclear about its recruitment status and plans to enroll 183 participants.

Study design
This is an open-label, multicenter Phase 1/2 study, meaning you and your doctors will know which treatment you are receiving. It involves a dose escalation phase to find the right dose, followed by a dose expansion phase.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will measure the maximum tolerated dose at 21 and 28 days, and how well the treatment works after 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06922591

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Recruiting
PHASE1Ages 18+InterventionalTreatment
Tango Therapeutics, Inc.
~183 participants
Updated 2026-05-14 on ClinicalTrials.gov
What's tested:TNG462RMC-9805RMC-6236mFOLFIRINOXgemcitabine/nab-paclitaxel

At a glance

Recruiting sites
18 of 18 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Phase 1: Maximum Tolerated Dose
Measured over 21 days
+2 more outcomes measured

Conditions

PDAC
PDAC - Pancreatic Ductal Adenocarcinoma
NSCLC
RAS Mutation
MTAP Deletion
Lung Cancer
Pancreatic Cancer Metastatic
Thoracic Cancer

Explore related trials

Lung Non-Small Cell CarcinomaPancreatic Ductal AdenocarcinomaMTAP Gene

Where it's being run

18 sites across 15 states
Massachusetts2
New York2
Texas2
Arizona1
Colorado1
District of Columbia1
Florida1
Illinois1

Study leadership

  • Maxim Pimpkin, MD, PhD · STUDY_DIRECTOR · Tango Therapeutics, Inc.

Who to contact

Maxim Pimpkin, MD, PhD
[email protected]
857-320-4899
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Phase 1: Maximum Tolerated Dose21 days

    To determine the MTD and RD(s) of TNG462 in combination with RMC-6236 or RMC-9805

  • Phase 1: Maximum Tolerated Dose28 days

    To determine the MTD and RD(s) of TNG462 in combination with mFOLFIRINOX or gemcitabine/nab-paclitaxel

  • Phase 2: Combination Anti-neoplastic Activity12 weeks

    To assess preliminary evidence of antineoplastic activity of TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel using RECIST 1.1